RxDoctor Payments Data

A Paul Kurkjian, MD

Child & Adolescent Psychiatry · Pasadena, CANPI 1134334550

Payments from drug & device makers

$362in general payments, 2019–2025

Across 4 payments — averaging $90.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$173
  • Sunovion Pharmaceuticals Inc.$125
  • Johnson & Johnson$64

What the payments were for

  • Food & beverage$362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362 in reported general payments places this provider in the 60th percentile of 434 child & adolescent psychiatry providers in California.

See all child & adolescent psychiatry providers in California

Medicare billing

Part B allowed, 2024
$332,668
Medicare patients
340
Services billed
2,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate63$208,020
Abilify MaintenaAripiprazole13$35,324
Aripiprazole OdtAripiprazole11$15,431
Olanzapine OdtOlanzapine163$13,646
Divalproex Sodium223$12,099
Quetiapine Fumarate ErQuetiapine Fumarate58$6,024
Fluoxetine Hcl96$5,443
Valproic AcidValproic Acid (As Sodium Salt)104$4,499
Clozapine54$4,397
Mirtazapine130$4,250
Quetiapine Fumarate187$3,555
Clonazepam227$3,098
Haloperidol Decanoate64$2,845
Haloperidol47$2,500
Olanzapine135$2,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$64$208,02063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 434 child & adolescent psychiatry providers in California.

Other child & adolescent psychiatry in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →